Pharmacodynamics

European Journal of Clinical Pharmacology

, Volume 67, Issue 11, pp 1109-1117

Open Access This content is freely available online to anyone, anywhere at any time.

The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia

  • Robert KrysiakAffiliated withDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia Email author 
  • , Anna Gdula-DymekAffiliated withDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia
  • , Boguslaw OkopienAffiliated withDepartment of Internal Medicine and Clinical Pharmacology, Medical University of Silesia

Abstract

Purpose

The aim of this study was to compare the effects of fibrates and omega-3 fatty acids on lymphocyte secretory function and systemic inflammation in patients with isolated hypertriglyceridemia.

Methods

The study included 107 patients with isolated hypertriglyceridemia who received bezafibrate (200 mg twice daily), omega-3 fatty acids (1 g twice daily) or placebo for 12 weeks. The lipid profile, fasting and 2-h post-glucose load plasma glucose levels, homeostasis model assessment index (HOMA), plasma high-sensitivity C-reactive protein (hsCRP) levels and lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α were assessed at baseline, on the day of randomization, and after 4 and 12 weeks of treatment.

Results

Both bezafibrate and omega-3 fatty acids reduced plasma triglyceride levels. Bezafibrate additionally decreased total and low-density lipoprotein-cholesterol levels and the HOMA and insignificantly decreased post-glucose load plasma glucose, as well as increased high-density lipoprotein-cholesterol. Bezafibrate treatment was associated with a reduction in lymphocyte release of interleukin-2, interferon-γ and tumor necrosis factor-α, which was accompanied by a reduction in plasma hsCRP levels. Omega-3 fatty acid did not significantly reduce lymphocyte cytokine release and plasma hsCRP. The anti-inflammatory effects of both drugs did not correlate with their action on plasma lipids, but in the case of the former the effect was related to the improvement in insulin sensitivity.

Conclusion

Our results indicate that bezafibrate is superior to omega-3 fatty acid in inhibiting systemic inflammation and lymphocyte secretory function.

Keywords

Bezafibrate Omega-3 fatty acids Isolated hypertriglyceridemia Lymphocytes Proinflammatory cytokines Low-grade inflammation